Brief: Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
17/12/2025 14:29
Dec 17 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. COMPLETES ENROLLMENT IN FDA-CLEARED ADAPT TRIAL FOR CELZ-201-OLASTROCEL, MARKING MAJOR CLINICAL INFLECTION POINT Source text: ID:nGNX1NYdWP Further company coverage: CELZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Holdings Achieves Second Who Inn Milestone
Brief: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial And Celz-201 (Olastrocel) In The Treatment Of Chronic Lower Back Pain
Brief: Creative Medical Technology Receives Approval For Biodefense Burn Pit Initiative
Brief: Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial
Brief: Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”